Applications of N-1-Boc-N-4-Cbz-2-Piperazinecarboxylic Acid T-Butyl Ester in Industrial Manufacturing

As a specialized producer of N-1-Boc-N-4-Cbz-2-Piperazinecarboxylic Acid T-Butyl Ester, we serve leading global manufacturers requiring high-purity piperazine derivatives for advanced chemical synthesis. Below, we present targeted downstream industrial scenarios, specifying integration details and regulatory compliance relevant to each application.

1. Peptide Active Pharmaceutical Ingredient (API) Development

This protected piperazinecarboxylic acid derivative is widely applied by peptide API producers as a building block for the synthesis of complex nitrogen-containing pharmaceutical intermediates, particularly in the development of small molecule drugs and peptidomimetics. Its dual-protected structure enables selective deprotection steps, supporting sequential synthesis under stringent GMP environments without cross-reactivity or racemization during peptide elongation or N-heterocyclic cyclization steps.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP <823>: Radiopharmaceuticals for Positron Emission Tomography–Compounding
• European Pharmacopoeia (Ph. Eur.) 2.2.46: Chromatographic separation techniques
• FDA 21 CFR Part 211: cGMP Current Good Manufacturing Practice for Finished Pharmaceuticals

Typical usage ratio

• Used at 0.8–1.2 mol equivalents relative to target amine or acid groups in solid-phase peptide synthesis; amount adjusted according to chain length and site-specific protection scheme required by the target compound.

Downstream process integration

• Integrated during the protected amide bond formation step on resin or in solution phase, contributing to the selective protection and subsequent deprotection in peptide sequence assembly.

Final product types

• Peptidomimetic APIs targeting CNS, anti-infective, and oncology indications
• Small molecule drugs featuring mono- or bis-piperazine scaffolds
• Peptide conjugates for pharmaceutical intermediates

2. Custom Chemical Synthesis for Contract Manufacturing Organizations (CMOs)

Specialty contract manufacturers select this material for multi-step organic synthesis projects demanding orthogonally protected piperazine derivatives. Its stability under acidic and basic conditions enables flexible use in parallel and multi-kilo synthesis where rigorous reproducibility is required for fluoroquinolone analogues, chemokine receptor modulators, and advanced intermediate production for investigational new drugs (INDs).

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• EudraLex Volume 4: EU Guidelines to Good Manufacturing Practice – Part II: Basic Requirements for Active Substances
• REACH Regulation (EC) No 1907/2006: Registration, Evaluation, Authorisation and Restriction of Chemicals
• ICH Q3A (R2): Impurities in New Drug Substances

Typical usage ratio

• Typically 1.0–1.3 equivalents as a protected amine placeholder; the precise dosage varies depending on the projected scale-up route and intermediate molecular structure, with batch-specific optimization during process validation.

Downstream process integration

• Added at the stage of amide or urea linkage formation in the synthetic pathway, particularly after stepwise functional group interconversions or as a masked nucleophilic center in late-stage intermediate assembly.

Final product types

• Clinical trial material batches of NDAs (New Drug Applications)
• Advanced heterocyclic intermediates
• API-grade custom molecules for lead optimization programs

3. Research Reagents for Medicinal Chemistry Laboratories

Major research-scale suppliers and in-house discovery chemistry divisions utilize our product as a core intermediate when developing protected piperazine motifs for structure–activity relationship (SAR) studies, library syntheses, and analog discovery campaigns. Its combination of Boc and Cbz protecting groups allows chemists to carry out orthogonal deprotection experiments for modifying piperazine-based scaffolds, relevant to hit-to-lead and fragment-based drug design projects.

Industry compliance standards

• ACS Guidelines for Chemical Laboratory Safety
• OECD Good Laboratory Practice (GLP) principles
• Sigma-Aldrich Purity Specifications for Research Reagents

Typical usage ratio

• Normally used from 0.9–1.1 molar equivalents with respect to the target heterocycle, adjusted based on planned scaffold elaboration and library scale.

Downstream process integration

• Employed in solution-phase or microwave-assisted batch reactions for parallel library construction, as well as in resin-supported synthesis for combinatorial chemistry.

Final product types

• Piperazine-based fragment libraries
• SAR test compounds for in vitro and cellular screening
• Custom research intermediates for academic and biotech partners

4. Key Intermediate in CNS Drug Candidate Synthesis

Pharmaceutical companies pursuing new chemical entities for central nervous system (CNS) disorders often require specialized piperazine intermediates with tailored protection groups. This material serves as a cornerstone to synthesize antipsychotics, antidepressants, and anxiolytics featuring diversified substitution patterns. Its defined steric protection streamlines multi-step syntheses where N-substitution or selective ring functionalization is critical for receptor binding and blood-brain barrier penetration profiles.

Industry compliance standards

• Japanese Pharmacopoeia (JP) for intermediates
• FDA Q11: Development and Manufacture of Drug Substances
• GMP for Active Pharmaceutical Ingredients (ICH Q7)

Typical usage ratio

• Applied at 1.0 equivalent per functionalization stage; ratio fine-tuned based on synthetic route density, target CNS molecule design, and processing yield optimization.

Downstream process integration

• Used following N-alkylation or N-acylation steps, providing a protected intermediate for further downstream cyclization, deprotection, and purification.

Final product types

• Piperazine-containing CNS drug candidates (e.g., antipsychotics and antidepressants under preclinical evaluation)
• Lead structure intermediates destined for clinical candidate nomination

5. Synthesis of Piperazine Linkers in Antibody–Drug Conjugate (ADC) Production

Biopharmaceutical manufacturers engaged in next-generation ADC pipeline development rely on this highly functionalized compound to construct stable cleavable or non-cleavable piperazine linkers. These linkers bridge monoclonal antibodies and cytotoxic payloads, with precise Boc and Cbz protections supporting targeted conjugation chemistry while maintaining linker integrity during payload installation and analytical release testing.

Industry compliance standards

• WHO Technical Report Series No. 986: Guidelines on GMP for Biological Products
• Ph. Eur. 2.6.27: Microbial examination of cell-based products
• USP <1047>: Gene Therapy Products
• CFR Title 21, Part 600–680: Biological Products

Typical usage ratio

• Generally 0.5–1.0 equivalent per linker molecule; precise ratio established according to antibody–payload stoichiometry and the conjugation methodology.

Downstream process integration

• Integrated post-antibody derivatization in linker–payload conjugation, prior to purification and ADC payload quantification; enables differential linker deprotection for controlled conjugation sites.

Final product types

• Cleavable or non-cleavable piperazine linkers for ADCs
• Pre-conjugation intermediates for immunotherapeutic drug candidates

6. Reference Standard Production for Analytical and Quality Control Laboratories

Chemical reference material producers and pharmaceutical QC departments implement this compound as a certified reference substance for the validation and calibration of analytical methods such as HPLC, NMR, and MS, particularly for pharmaceutical products containing piperazine scaffolds. Its purity and well-defined structure support the creation of secondary standards and ensure traceability in lot release and impurity profiling processes.

Industry compliance standards

• ISO 17034:2016 General requirements for the competence of reference material producers
• USP <1224>: Transfer of Analytical Procedures
• Ph. Eur. 5.12: Reference Standards

Typical usage ratio

• Employed as 1–10 mg per calibration or system suitability sample, amount chosen according to specific analytical method requirements and laboratory SOPs.

Downstream process integration

• Manufactured into high-purity reference standards and distributed for use in calibration of chromatographic and spectroscopic equipment during pharmaceutical in-process and finished product testing.

Final product types

• Certified reference standards for method validation
• System suitability test solutions for regulated pharmaceutical analyses